Novartis’ Enablex To Enter Crowded Urinary Incontinence Market In Early ‘05
Executive Summary
Novartis plans to enter the urinary incontinence market in early 2005 with the launch of its newly approved overactive bladder therapy Enablex
You may also be interested in...
Overactive Bladder Ads Become Frequent; 3 DTC Spots Break In Last 2 Months
Pfizer, Johnson & Johnson and GlaxoSmithKline/ Yamanouchi have each released new direct-to-consumer TV advertisements for their overactive bladder products in the last two months as the sector has become more competitive
Overactive Bladder Ads Become Frequent; 3 DTC Spots Break In Last 2 Months
Pfizer, Johnson & Johnson and GlaxoSmithKline/ Yamanouchi have each released new direct-to-consumer TV advertisements for their overactive bladder products in the last two months as the sector has become more competitive
Pfizer Expects Menstrually-Associated Migraine Claim For Relpax
Pfizer expects Relpax (eletriptan) to be the first triptan to receive a labeling claim for relief of menstrually-associated migraines.